Loading
ST
Summit Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by DUGGAN ROBERT W, was filed 04 Jun 2026.
Insider Decl.
66
Thresholds
n/a
Buy Volume
€626M
33 ops. · all time
Sell Volume
€269,951
5 ops. · all time
Who traded when
BuySaleRobert W. Duggan4 buys
Mahkam Zanganeh3 buys
Yu Xia1 buy
Since the insiders bought
- -0.9%Entry US$14.77 · Close 16 Oct 2026 US$14.63
- -9.9%Entry US$19.28 · Close at T+90 US$17.37
- -9.9%Entry US$19.28 · Close at T+90 US$17.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Summit Therapeutics Inc. Buy (bullish), based on 13 analysts. Average price target: US$30.31.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.09
Analyst consensus
13 analystsBuy
US$12.04Target US$30.31(+88%)US$43.75
Income statement
Gross profit-US$21.8M
EBITDA-US$1.1B
Net income-US$1.1B0.0% margin
Valuation
PER (forward)-18.3x
P/Book20.3x
Beta-1.52
Balance sheet & cash
Market capUS$12.8B
Total debtUS$20.9M
Free Cash Flow-US$323.6M
Debt / Equity3%
Profitability & ownership
ROE-192.5%
ROA-101.6%
% insiders80.7%
% institutions17.6%
Last declaration on 14 October 2026
Declarations66 total
100,000 shares0Common StockSEC:0001890784-26-000006:0
100,000 shares@ US$14.600.012% mcap2.5% of flowCommon StockSEC:0001055919-26-000005:0
Canonical exit: 2 Sept 2026 (T+90)
26,680 shares@ US$18.740.2% of flowCommon StockSEC:0001507650-25-000003:1
Canonical exit: 19 Jan 2026 (T+90)
13,980,789 shares@ US$18.7479.4% of flowCommon StockSEC:0001507650-25-000003:2
266,808 shares@ US$18.740.5% of flowCommon StockSEC:0001055919-25-000003:1
26,680 shares@ US$18.740.0% of flowCommon StockSEC:0001055919-25-000003:2
Canonical exit: 19 Jan 2026 (T+90)
533,617 shares@ US$18.74100.0% of flowCommon StockSEC:0001963544-25-000004:0
Canonical exit: 19 Jan 2026 (T+90)
26,680 shares@ US$18.7448.7% of flowCommon StockSEC:0001890784-25-000005:0
53,361 shares@ US$18.7413.2% of flowCommon StockSEC:0001569769-25-000002:0
266,808 shares@ US$18.748.6% of flowCommon StockSEC:0001507650-25-000003:0
13,980,789 shares@ US$18.7429.4% of flowCommon StockSEC:0001055919-25-000003:0
5,000 shares@ US$18.070.0% of flowCommon StockSEC:0001599298-25-000143:1
Canonical exit: 10 Dec 2025 (T+90)
5,000 shares@ US$18.070.0% of flowCommon StockSEC:0001599298-25-000142:1
Canonical exit: 10 Dec 2025 (T+90)
333,394 shares@ US$17.680.7% of flowCommon StockSEC:0001599298-25-000142:0
Canonical exit: 9 Dec 2025 (T+90)
333,394 shares@ US$17.6810.1% of flowCommon StockSEC:0001599298-25-000143:0
Canonical exit: 9 Dec 2025 (T+90)
74,545 shares@ US$2.640.3% of flowCommon StockSEC:0001599298-25-000107:0
74,545 shares@ US$2.640.0% of flowCommon StockSEC:0001599298-25-000106:0
3,985,055 shares@ US$1.580.7% of flowCommon StockSEC:0001599298-25-000058:0
3,985,055 shares@ US$1.5811.5% of flowCommon StockSEC:0001599298-25-000060:0
315,681 shares@ US$1.580.9% of flowCommon StockSEC:0001599298-24-000146:0
44,052 shares@ US$22.7013.9% of flowCommon StockSEC:0001599298-24-000136:0
44,052 shares@ US$22.70100.0% of flowCommon StockSEC:0001599298-24-000138:0
3,325,991 shares@ US$22.708.9% of flowCommon StockSEC:0001599298-24-000139:0
44,052 shares@ US$22.701.8% of flowCommon StockSEC:0001599298-24-000141:0
22,026 shares@ US$22.7051.3% of flowCommon StockSEC:0001599298-24-000135:0
25 of 66 declarations
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a US healthcare company valued at USD 12.8 billion and 80.7% held by insiders, shows 33 purchases worth EUR 625,625,842 (median EUR 431,006), which is 87% of open-market trades, against 5 sales worth EUR 269,951. Robert W. Duggan (Chief Executive Officer) is behind the three largest purchases: EUR 372,018,514 on March 6, 2023, EUR 90,459,906 on August 16, 2022 and EUR 49,308,604 on May 12, 2021.
On October 21, 2025, three filers bought EUR 9,482,396. Mahkam Zanganeh (Co-Chief Executive Officer) signs the most filings, 21, of which 12 purchases; Robert W. Duggan signs 15, 8 of them purchases. Ankur Dhingra (Chief Financial Officer) has 7 filings, all purchases, and Maky Zanganeh (Co-CEO & President) 4 out of 4. The sales all belong to David Jonathan Powell (Chief Scientific Officer), the largest being EUR 108,936 on November 27, 2020.
Read moreShow less
The 66 filings include 17 grants and 8 option exercises. The 33 purchases have a 90-day median of 16%, with 67% positive: stored past results, not a forecast. The annual peak is 17 in 2025; the last twelve months hold 11 filings, of which 4 purchases and no sale.
